Envista Holdings (NVST) Research & Development (2018 - 2026)
Envista Holdings' (NVST) quarterly Research & Development came in at $30.0 million in Q2 2026, up 18.58% year-on-year from $25.3 million in Q2 2025, and down 6.54% quarter-over-quarter from $32.1 million in Q4 2025.
Envista Holdings (NVST) Research & Development (2018 - 2026) Analysis & Trends
Envista Holdings' Research & Development history runs 9 years deep, the most recent figure standing at $30.0 million for Q2 2026.
- On a quarterly basis, Research & Development rose 18.58% year-over-year to $30.0 million in Q2 2026; TTM through Apr 2026 was $118.7 million, a 17.41% increase from a year earlier, with the FY2025 full-year figure at $114.0 million, up 15.04% from the prior year.
- Research & Development eased to $30.0 million in Q2 2026 per NVST's latest filing, from $32.1 million in the prior quarter.
- Across five years, Research & Development topped out at $32.1 million in Q4 2025 and bottomed at $20.2 million in Q4 2023.
- The 5-year median for Research & Development is $25.3 million (2025), against an average of $25.7 million.
- Across the five-year window, Research & Development dropped 17.89% in 2023 and surged 32.18% in 2024, its largest moves.
- Year by year, Research & Development stood at $24.6 million in 2022, then declined by 17.89% to $20.2 million in 2023, then soared by 32.18% to $26.7 million in 2024, then grew by 20.22% to $32.1 million in 2025, then slipped by 6.54% to $30.0 million in 2026.
- Per Business Quant, the three latest NVST Research & Development figures stand at $30.0 million (Q2 2026), $32.1 million (Q4 2025), and $28.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 33,163,703.85 Bn | 33,163,702.19 Bn | 1.53 Bn | -245.00 Mn |
| 2 | Intuitive Surgical | 119.67 Bn | 114.45 Bn | 1.96 Bn | 370.60 Mn |
| 3 | Becton Dickinson | 43.92 Bn | 43.11 Bn | 2.15 Bn | 249.00 Mn |
| 4 | Medline | 31.71 Bn | 29.47 Bn | 1.84 Bn | - |
| 5 | Resmed | 28.46 Bn | 26.80 Bn | 890.98 Mn | 94.27 Mn |
| 6 | West Pharmaceutical Services | 23.80 Bn | 23.28 Bn | 296.40 Mn | 15.80 Mn |
| 7 | Cooper Companies | 13.77 Bn | 13.63 Bn | 735.40 Mn | 42.50 Mn |
| 8 | Solventum | 13.63 Bn | 13.06 Bn | 1.10 Bn | 189.00 Mn |
| 9 | Align Technology | 11.94 Bn | 10.88 Bn | 736.59 Mn | 98.66 Mn |
| 10 | Envista Holdings | 4.34 Bn | 3.26 Bn | 390.10 Mn | 30.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 30.00 Mn |
| Dec 31, 2025 | 32.10 Mn |
| Sep 26, 2025 | 28.30 Mn |
| Jun 27, 2025 | 28.30 Mn |
| Mar 28, 2025 | 25.30 Mn |
| Dec 31, 2024 | 26.70 Mn |
| Sep 27, 2024 | 25.50 Mn |
| Jun 28, 2024 | 23.60 Mn |
| Mar 29, 2024 | 23.30 Mn |
| Dec 31, 2023 | 20.20 Mn |
| Sep 29, 2023 | 22.30 Mn |
| Jun 30, 2023 | 26.80 Mn |
| Mar 31, 2023 | 24.50 Mn |
| Dec 31, 2022 | 24.60 Mn |
| Sep 30, 2022 | 26.00 Mn |
| Jul 1, 2022 | 25.10 Mn |
| Apr 1, 2022 | 24.40 Mn |
| Dec 31, 2021 | 24.80 Mn |
| Oct 1, 2021 | 24.00 Mn |
| Jul 2, 2021 | 25.90 Mn |